Jonathan A. Meulbroek

3.3k total citations · 1 hit paper
17 papers, 2.0k citations indexed

About

Jonathan A. Meulbroek is a scholar working on Molecular Biology, Infectious Diseases and Pharmaceutical Science. According to data from OpenAlex, Jonathan A. Meulbroek has authored 17 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Infectious Diseases and 4 papers in Pharmaceutical Science. Recurrent topics in Jonathan A. Meulbroek's work include Advanced Drug Delivery Systems (4 papers), Immunotherapy and Immune Responses (3 papers) and Antifungal resistance and susceptibility (2 papers). Jonathan A. Meulbroek is often cited by papers focused on Advanced Drug Delivery Systems (4 papers), Immunotherapy and Immune Responses (3 papers) and Antifungal resistance and susceptibility (2 papers). Jonathan A. Meulbroek collaborates with scholars based in United States, United Kingdom and Australia. Jonathan A. Meulbroek's co-authors include Jay K. Staas, Richard M. Gilley, John H. Eldridge, Thomas R. Tice, Jerry R. McGhee, Zina Moldoveanu, Fritz G. Buchanan, David J. Frost, Hugh D. Falls and Peter J. DeVries and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Journal of Controlled Release.

In The Last Decade

Jonathan A. Meulbroek

17 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches

1990 588 citations John H. Eldridge, Jonathan A. Meulbroek et al. Journal of Controlled Release profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan A. Meulbroek United States	14	683	623	507	351	270	17	2.0k
Jay K. Staas United States	16	699 1.0×	830 1.3×	726 1.4×	436 1.2×	395 1.5×	20	2.2k
Richard M. Gilley United States	20	863 1.3×	1.0k 1.7×	809 1.6×	453 1.3×	412 1.5×	31	2.8k
R Audran Switzerland	21	877 1.3×	229 0.4×	928 1.8×	385 1.1×	325 1.2×	63	2.5k
Vincent W. Bramwell United Kingdom	22	905 1.3×	426 0.7×	917 1.8×	264 0.8×	230 0.9×	32	1.8k
M. Ann Clark United Kingdom	22	823 1.2×	446 0.7×	782 1.5×	407 1.2×	138 0.5×	30	2.2k
Pål Johansen Switzerland	39	1.3k 2.0×	821 1.3×	1.8k 3.6×	386 1.1×	340 1.3×	115	4.9k
Inderjit Jabbal‐Gill United Kingdom	19	723 1.1×	1.1k 1.7×	560 1.1×	176 0.5×	330 1.2×	20	2.0k
Bryan H. Bellaire United States	25	562 0.8×	192 0.3×	455 0.9×	146 0.4×	292 1.1×	54	1.6k
Shau Ku Huang United States	15	649 1.0×	197 0.3×	426 0.8×	148 0.4×	83 0.3×	20	2.2k
Seyoum Ayehunie United States	24	465 0.7×	168 0.3×	945 1.9×	440 1.3×	358 1.3×	52	2.6k

Countries citing papers authored by Jonathan A. Meulbroek

Since Specialization

Citations

This map shows the geographic impact of Jonathan A. Meulbroek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan A. Meulbroek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan A. Meulbroek more than expected).

Fields of papers citing papers by Jonathan A. Meulbroek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan A. Meulbroek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan A. Meulbroek. The network helps show where Jonathan A. Meulbroek may publish in the future.

Co-authorship network of co-authors of Jonathan A. Meulbroek

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan A. Meulbroek. A scholar is included among the top collaborators of Jonathan A. Meulbroek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan A. Meulbroek. Jonathan A. Meulbroek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Phillips, Andrew C., Erwin R. Boghaert, Kedar S. Vaidya, et al.. (2016). ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. Molecular Cancer Therapeutics. 15(4). 661–669. 136 indexed citations

Reilly, Edward B., Andrew C. Phillips, Fritz G. Buchanan, et al.. (2015). Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Molecular Cancer Therapeutics. 14(5). 1141–1151. 62 indexed citations

Pappano, William N., Paul Jung, Jonathan A. Meulbroek, et al.. (2009). Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605. BMC Cancer. 9(1). 314–314. 14 indexed citations

Wang, Jieyi, Lora A. Tucker, Jason Stavropoulos, et al.. (2008). Correlation of tumor growth suppression and methionine aminopetidase-2 activity blockade using an orally active inhibitor. Proceedings of the National Academy of Sciences. 105(6). 1838–1843. 25 indexed citations

Stavropoulos, Jason, Jonathan A. Meulbroek, Jacqueline M. O’Connor, et al.. (2005). Preclinical activity of ABT-869, a novel receptor tyrosine kinase inhibitor, alone or in combination with paclitaxel. Journal of Clinical Oncology. 23(16_suppl). 3175–3175. 4 indexed citations

Meulbroek, Jonathan A., Angela M. Nilius, Qun Li, et al.. (2003). In vivo characterization of A-192411: a novel fungicidal lipopeptide (II). Bioorganic & Medicinal Chemistry Letters. 13(3). 495–497. 1 indexed citations

Mitten, Michael J., Jonathan A. Meulbroek, Anatol Oleksijew, et al.. (2001). Efficacies of ABT-773, a New Ketolide, against Experimental Bacterial Infections. Antimicrobial Agents and Chemotherapy. 45(9). 2585–2593. 24 indexed citations

Ma, Zhenkun, Daniel T. W. Chu, Curt S. Cooper, et al.. (1999). Synthesis and Antimicrobial Activity of 4H-4-Oxoquinolizine Derivatives: Consequences of Structural Modification at the C-8 Position. Journal of Medicinal Chemistry. 42(20). 4202–4213. 54 indexed citations

Wolf, Bryan W., et al.. (1997). Dietary Supplementation with Fructooligosaccharides Increase Survival Time in a Hamster Model of Clostridium difficile-Colitis. 16(2). 59–64. 17 indexed citations

10.

Sarthy, Aparna V., Thomas McGonigal, Michael Coen, et al.. (1997). Phenotype in Candida albicans of a disruption of the BGL2 gene encoding a 1,3-β-glucosyltransferase. Microbiology. 143(2). 367–376. 86 indexed citations

11.

Meulbroek, Jonathan A., Anatol Oleksijew, S. Ken Tanaka, & Jeffrey Alder. (1996). Efficacy of ABT-719, a 2-pyridone antimicrobial, against enterococci, Escherichia coli, and Pseudomonas aeruginosa in experimental murine pyelonephritis. Journal of Antimicrobial Chemotherapy. 38(4). 641–653. 6 indexed citations

12.

Alder, Jeff, Jacob J. Clement, Jonathan A. Meulbroek, et al.. (1995). Efficacies of ABT-719 and related 2-pyridones, members of a new class of antibacterial agents, against experimental bacterial infections. Antimicrobial Agents and Chemotherapy. 39(4). 971–975. 15 indexed citations

13.

Eldridge, John H., Jay K. Staas, Jonathan A. Meulbroek, Thomas R. Tice, & Richard M. Gilley. (1991). Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infection and Immunity. 59(9). 2978–2986. 322 indexed citations

14.

Eldridge, John H., Jay K. Staas, Jonathan A. Meulbroek, et al.. (1991). Biodegradable microspheres as a vaccine delivery system. Molecular Immunology. 28(3). 287–294. 332 indexed citations

15.

Eldridge, John H., et al.. (1990). Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches. Journal of Controlled Release. 11(1-3). 205–214. 588 indexed citations breakdown →

16.

Eldridge, John H., Richard M. Gilley, Jay K. Staas, et al.. (1989). Biodegradable Microspheres: Vaccine Delivery System for Oral Immunization. Current topics in microbiology and immunology. 146. 59–66. 169 indexed citations

17.

Eldridge, John H., Jonathan A. Meulbroek, Jay K. Staas, Thomas R. Tice, & Richard M. Gilley. (1989). Vaccine-Containing Biodegradable Microspheres Specifically Enter the Gut-Associated Lymphoid Tissue Following Oral Administration and Induce a Disseminated Mucosal Immune Response. PubMed. 251. 191–202. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact